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The objective of this study was to evaluate the feasibility of fertility preservation
in cancer patients by combined bilateral ovarian cortex cryopreservation and
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Document type : Article de périodique (Journal article)
Référence bibliographique
Dolmans, Marie-Madeleine ; Marotta, Maria-Laura ; Pirard, Céline ; Donnez, Jacques ; Donnez,
Olivier. Ovarian tissue cryopreservation followed by controlled ovarian stimulation and pick-up of
mature oocytes does not impair the number or quality of retrieved oocytes.. In: Journal of Ovarian
Research, Vol. 7, no.1, p. 80 (2014)
DOI : 10.1186/s13048-014-0080-8
RESEARCH Open Access
Ovarian tissue cryopreservation followed by
controlled ovarian stimulation and pick-up of
mature oocytes does not impair the number or
quality of retrieved oocytes
Marie-Madeleine Dolmans1*†, Maria-Laura Marotta2†, Céline Pirard1, Jacques Donnez3 and Olivier Donnez2
Abstract
Background: The objective of this study was to evaluate the feasibility of fertility preservation in cancer patients by
combined bilateral ovarian cortex cryopreservation and embryo freezing.
Methods: This was a cohort-controlled study in a university hospital center. Sixteen patients with a recent cancer
diagnosis were included in the study. They all consented to fertility preservation by a combined technique: ovarian
tissue cryopreservation (OTC) followed by ovarian stimulation for in vitro fertilization (IVF) and embryo freezing. The
control group included 100 women of the same age undergoing IVF for male factor infertility.
Results: The mean number of metaphase II oocytes was 8.3 per patient (±7.7) and was not statistically different
from the control group (8.1 ± 5.6). The mean number of good quality embryos obtained was not statistically
different in the 2 groups (4.2 versus 4.4).
Conclusion: OTC before embryo freezing does not impair the number or quality of cryopreserved embryos, but
increases fertility preservation potential.
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Introduction
In recent decades, improvements in cancer survival rates
in children and young adults have stimulated interest in
fertility preservation (FP) techniques. Indeed, therapies
which greatly increase life expectancy also accelerate oo-
cyte depletion, leading to early menopause [1]. This risk of
premature ovarian failure depends on the age of the pa-
tient at the time of gonadotoxic treatment and the type of
chemo- and/or radiotherapy protocol (dose and number
of cycles) applied [1-3]. Several options are currently avail-
able to preserve fertility in patients with cancer, including
embryo cryopreservation, oocyte cryopreservation and
ovarian tissue cryopreservation (OTC). The American
Society for Reproductive Medicine (ASRM) has endorsed
embryo and oocyte cryopreservation, but still considers
OTC an experimental technique [4-7], even if in some
conditions, especially in prepubertal girls or when imme-
diate chemotherapy is required, there is no alternative at
present [7-9].
There are, however, some limitations to performing
oocyte or embryo cryopreservation in cancer patients.
Studies by Rienzi et al. and Cobo et al. show that around
20 oocytes are required to achieve a live birth [4,5]. This
number can be obtained in egg donation programs or in
case of FP for social reasons, but rarely in women with
cancer. Even when a delay in treatment is possible, it is
usually for no more than one cycle [5,6]. Thus, the good
results obtained in egg donation programs cannot be ex-
trapolated to cancer patients, nor can the quality of eggs
be guaranteed in these women [5,7].
To maximize the chances of FP, we propose a combined
technique: 1) OTC and 2) in vitro fertilization (IVF) treat-
ment to cryopreserve embryos.
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The aim of this study was to evaluate if bilateral biopsy
and OTC followed by controlled ovarian stimulation
(COS) is a feasible method to preserve fertility without
any negative impact on the number of oocytes.
Patients and methods
Patients
After adequate counseling, patients referred to our institu-
tion for FP were offered cryopreservation of both ovarian
cortex and embryos, depending on their marital status,
the type of cancer, and the time interval before beginning
oncological treatment [7].
Sixteen patients (study group) suffering from cancer
and undergoing OTC followed by COS were included in
the study (Table 1). All the women had regular ovulatory
cycles (25–32 days) at the time of diagnosis. Eight
patients were diagnosed with hematological malignan-
cies (Hodgkin’s disease (n = 6), non-Hodgkin’s disease
(n = 2)), and the rest with infiltrating ductal carcinoma
(n = 4), colon cancer (n = 2), ovarian cancer (n = 1) and
abdominal Ewing’s sarcoma (n = 1). They all needed
chemotherapy (+ radiotherapy in 7 cases) (Table 1). It is
important to note that none of them had undergone
chemotherapy or radiotherapy before FP.
The control group (n = 100) included age-matched
patients undergoing IVF treatment for male factor infertil-
ity. Intracytoplasmic sperm injection (ICSI) was required
for all control group cases (inclusion criteria: Kruger
morphology <5%).
Patients referred for FP in our institution were seen in
an emergency context. The OTC protocol was approved
by the institutional review board of the Cliniques universi-
taires Saint-Luc. After obtaining informed consent, bilat-
eral biopsy by laparoscopy and OTC were performed as
soon as possible. COS was started one or two days before
laparoscopy or on the same day. The type of stimulation
administered depended on the patient cycle phase at the
time of laparoscopy. Patients in the follicular phase re-
ceived a short agonist or antagonist protocol, while those
in the luteal phase received a long agonist protocol. Go-
nadotropins used were recombinant (Gonal-F®, Merck-
Serono, Darmstadt, Germany) or urinary purified (Meno-
pur®, Ferring, Kiel, Germany). Trigger was performed by
subcutaneous injection of human chorionic gonadotropin
(hCG) (Pregnyl®, MSD, Hertforshire, UK) when the dom-
inant follicle reached at least 15-16 mm in size. Based on
their cycle phase, 3 study patients and 9 control patients
were assigned a long agonist protocol, 3 study patients
and 4 control patients a short agonist protocol, and 10
study patients and 87 control patients an antagonist proto-
col. The 4 patients suffering from breast cancer were older
than the others (range: 31-34 y) and did not receive any
specific stimulation treatment such as letrozole.
Consent
Patients gave their informed consent for their medical and
administrative data to be communicated to external bod-
ies in a coded manner.
Table 1 Characteristics of cancer patients, type of cancer and adjuvant treament
Age Type of cancer Type of chemotherapy Body or pelvic irradiation
1 26 Ovarian carcinoma Carbotaxol -
2 25 NHD(a) ABVD -
3 26 HD(b) ABVD 30 Gy
4 23 HD(b) ABVD -
5 24 HD(b) R-CHOP -
6 28 Colon cancer FOLFOX -
7 31 IDC(c) Unknown Breast
8 25 Abdominal Ewing’s sarcoma VIDE 45 Gy
9 32 NHD(a) CHOPP -
10 25 HD(b) BEACOPP + ABVD -
11 34 IDC(c) Unknown Breast
12 23 HD(b) BEACOPP + ABVD -
13 34 IDC(c) FEC Breast
14 21 HD(b) Unknown Unknown
15 32 IDC(c) FEC – taxotere Breast
16 24 Colon cancer FOLFOX -
(a)NHD: non-Hodgkin’s disease.
(b)HD: Hodgkin’s disease.
(c)IDC: infiltrating ductal carcinoma.
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Statistical analyses
Data are presented as mean +/−standard deviation.
Statistical analyses were performed using the Mann–
Whitney U-test with GraphPad Prism (version 4.00 for
Windows, GraphPad Software, San Diego, California,
USA, www.graphpad.com). A p-value of less than 0.05 was
considered statistically significant.
Results
Patient age was 27.1 ± 4.2 years (range: 21-34 y) in the
study group and 28 ± 2.6 years (range: 21-33 y) in the con-
trol group, which was not statistically different (p = 0.1744)
(Table 2).
The duration of stimulation was 10.1 ± 2.8 days in the
study group and 10.8 ± 3.3 days in the control group,
with no statistically significant difference (n = 0.7687)
(Table 2). The total dose of gonadotropins used was
2440 ± 994 IU and 1681 ± 695 IU in the study and control
groups respectively. The total dose of gonadotropins used
was statistically higher in the study group (p = 0.0017*).
The estradiol level reached at the time of hCG trigger was
1350 ± 1742 pg/ml in the study group and 959 ± 713 pg/
ml in the control group, showing no statistically signifi-
cant difference between the 2 groups (p = 0.8596)
(Table 2).
Oocyte pick-up
The number of collected oocytes was not statistically dif-
ferent between the 2 groups, with 10.7 ± 9.9 oocytes per
study patient and 10.8 ± 6.2 oocytes per control patient
(p = 0.3716) (Table 2). The number of mature oocytes
(MII) per patient was 8.3 ± 7.7 in the study group and
8.1 ± 5.6 in the control group, again showing no statisti-
cally significant difference (p = 0.5812).
Fertilization results
In the study group, all mature oocytes were microin-
jected with the partner’s spermatozoa by ICSI to avoid
the risk of failed fertilization. In the control group, all
couples underwent ICSI for male factor infertility.
In the study group, the number of good quality embryos
obtained per patient was 4.2 ± 5.0 and they were all cryo-
preserved on day 2 or 3. In the control group, 4.4 ± 4.1
good quality embryos were obtained per patient on day 3
(Table 2). There was no statistically significant difference
between the 2 groups (p = 0.1676).
Breast cancer patients
The ovarian response was variable among the 4 patients
suffering from breast cancer, so no statistical analyses
could be carried out. One patient had no embryos cryo-
preserved, while another had 17 embryos cryopreserved.
Discussion
Cryopreservation of embryos is the most widely estab-
lished method of FP, but is essentially applicable to adult
women with a stable male partner [7,10-14]. In the lit-
erature, survival rates of cryopreserved embryos and vit-
rified mature oocytes after thawing are reported to be
80-90%, while pregnancy rates are comparable to those
recorded with fresh oocytes [4,5].
However, it should be pointed out that these results
were obtained in non-cancer patients and that adequate
numbers of oocytes need to be collected. Recent reviews
by Rienzi et al. [4] and Cobo et al. [5] suggest that around
20 mature oocytes are required to achieve a live birth. An
immediate obstacle is the fact that only one COS cycle
can usually be performed in cancer patients, yielding a
‘relatively’ low number of oocytes (and embryos). For this
reason, results from egg donation programs cannot be
extrapolated to cancer patients, nor can the quality of
oocytes be guaranteed.
Very little literature is available on pregnancy rates in
cancer survivors after frozen-thawed embryo transfer,
because the majority of embryos frozen for FP have not
yet been transferred [5,10,13-16]. Barcroft et al. recently
published their 15-year follow-up of patients undergo-
ing embryo cryopreservation for FP, obtaining 2 live
births and 1 miscarriage after 9 embryo transfers in 5
patients [16].
Table 2 Patient and stimulation characteristics and outcome
Study group (n = 16) Control group (n = 100) p value
Age (years) 27.1 y (+/− 4.2) 28 (+/− 2.6) 0.1744 ns
Stimulation duration 10.1 days (+/− 2.8) 10.8 days (+/− 3.3) 0.7687 ns
Total dose of gonadotropins 2440 IU (+/− 994) 1681 IU (+/− 695) 0.0017*
E2 level on the DhCG 1350 pg/ml (+/− 1742) 959 pg/ml (+/− 713) 0.8596 ns
Number of retrieved oocytes 10.7 (+/− 9.9) 10.8 (+/− 6.2) 0.3716 ns
Number of mature oocytes (MII) 8.3 (+/−7.7) 8.1 (+/− 5.6) 0.5812 ns
Number of good quality embryos 4.2 (+/− 5.0) 4.4 (+/− 4.1) 0.1676 ns
Data are presented as mean +/- standard deviation. DhCG: day of human chorionic gonadotropin injection/E2: estradiol/IVF: in vitro fertilization/MII: metaphase II/
ns: not statistically significant.
(*)statistically significant (p-value < 0.05).
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In women with cancer, embryo or oocyte cryopreser-
vation techniques yield a limited number of embryos for
transfer [6,17], and there is often only time to perform
one COS cycle before starting oncological treatment
[6,7,10,18]. Combining these techniques with OTC could
therefore be considered an alternative approach.
In our study, 8.3 and 8.1 MII oocytes were respectively
retrieved from cancer patients and control patients (of
the same mean age), and the number of good quality
embryos obtained was respectively 4.2 ± 5 and 4.4 ± 4.1.
Our study proves that OTC performed just before the
start of COS or even on day 1 or 2 of stimulation does
not affect the number of mature oocytes and embryos
obtained, which was similar to the control group.
In the literature, two studies by Huober-Zeeb et al.
[19] and Dittrich et al. [20] report the results of a com-
bined technique (OTC and COS) for FP, but using two
different sequences.
Huober-Zeeb et al. [19] compared two cancer patient
groups. In the study group, they cryopreserved half of
one ovary, followed by COS and IVF, and compared
their results with the control group, who also underwent
COS and IVF treatment for FP, but without previous
OTC. They did not find any difference between these 2
cancer groups in terms of duration of stimulation (mean
10.2 days vs 10.6 days in the study and control groups
respectively), total dose of gonadotropins, or total num-
ber of retrieved oocytes per patient (mean 12.1 vs 13.1).
Very recently, Dittrich et al. [20] conducted a retrospect-
ive study in cancer patients with cryopreservation of half of
one ovary on the same day as oocyte pick-up (OPU) after
IVF stimulation. The average number of oocytes retrieved
per patient was 10, and 67% of them were successfully fer-
tilized by ICSI. The authors did not note any perioperative
complications, but it is known that vascularization of the
corpus luteum is greater in the early luteal phase. It should
be pointed out that OPU 34-36 hours after hCG adminis-
tration followed by ovarian tissue biopsy may cause severe
bleeding due to the presence of multiple earlier corpora
lutea, which are very highly vascularized. It was indeed
reported that, for the same reason, the ovarian tissue was of
poor quality for cryopreservation (C.Y. Andersen, personal
communication).
Ovarian stimulation requires time and it is recognized
that this procedure needs to be performed before the
first cycle of chemotherapy [21]. Dolmans and colleagues
clearly demonstrated that only very few poor quality em-
bryos were obtained when IVF was attempted immediately
after one or two courses of chemotherapy. Ovarian stimu-
lation should therefore no longer be offered for OPU after
chemotherapy. Moreover, Meirow et al. reported high
rates of malformation in offspring after treatment with
cyclophosphamide (in an experimental model) [22]. In our
study, the time between OTC and OPU was short (mean
14.8 days). This interval could be further shortened using
modified IVF treatments, such as antagonist injection dur-
ing the luteal phase to induce luteolysis [6,10,23-28].
Removal of approximately 50% of one ovary for cryo-
preservation in Dittrich’s study had only a limited impact
on the number, quality and fertilization potential of oo-
cytes. When compared with our study, which investi-
gated the number of MII oocytes and embryos in cancer
patients, we could add that removal of approximately
20% of ovarian cortex from each ovary did not result in
fewer oocytes the control group, leading us to suggest
that it is maybe more appropriate to remove no more
than 20% if IVF and embryo cryopreservation are subse-
quently planned. No bleeding was observed after OPU
in our study, nor in that of Huober-Zeeb et al. [19].
Concerning the number of oocytes retrieved from cancer
patients, there is still some debate. A meta-analysis con-
cluded that the mean number of oocytes is lower in women
with cancer [29], but Tulandi and Holzer found that malig-
nancies do not affect the number of oocytes [30]. Our
study, although limited, failed to observe any significant dif-
ference between cancer and non-cancer patients of the
same age. Nevertheless, due to this discrepancy, it is
strongly advised that patients be informed that the number
of oocytes may be lower than expected due to the accom-
panying neoplasm [6]. The total dose of gonadotropins
used in the study group was significantly higher than in the
control group. Reasons for this include the potential risk of
obtaining fewer embryos because of the neoplasm, con-
cerns about having no embryos to cryopreserve in patients
able to undergo only one cycle, and the desire to cryopre-
serve as many embryos as possible. However, none of our
patients had to delay their oncological treatment due to hy-
perstimulation syndrome. Indeed, using GnRH agonists to
trigger ovulation before OPU has been shown to dramatic-
ally lower the risk of ovarian hyperstimulation syndrome
[6,10,24] and shorten the luteal phase, possibly allowing a
second COS if feasible [18,28,31,32].
Theoretically, IVF treatments induce high estradiol
levels that could be deleterious to hormone-sensitive can-
cers like breast cancer. To avoid this effect, ovarian stimu-
lation with letrozole and antagonist has been proposed
[31]. In this case, the letrozole or antagonist should be
continued after OPU to precipitate a decrease in estradiol
levels [10,31,32]. In our series, even in non-metastatic
breast cancer and lymph node-negative breast cancer, clas-
sical COS was used, as we (gynecologists and oncologists)
consider that there is no evidence that 4–5 days of high
estradiol levels may be deleterious for patients or impact
their survival.
Conclusion
In the present study, we demonstrate that cryopreserva-
tion of bilateral ovarian cortex followed by IVF treatment
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is a feasible and safe approach to preserve fertility before
oncological treatment. The number of cryopreserved em-
bryos obtained was not statistically different from the con-
trol group and not affected by the previous bilateral
biopsy for OTC. Moreover, this technique does not delay
oncological treatment. It may even be proposed to patients
without a male partner in association with oocyte
vitrification.
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